InMode reiterates FY 2026 guidance of $365M–$375M while reporting Q2 preliminary results above market expectations, despite active acquisition process.
InMode has reported preliminary Q2 2026 revenue guidance of $95.2 million to $95.4 million, tracking above consensus estimates and reiterating full-year 2026 revenue guidance of $365 million to $375 million. The company will report full Q2 results on August 5, 2026.
The guidance beat comes as InMode navigates competing acquisition proposals—the CEO-led buyout and Steel Partners' unsolicited $16.75/share bid. Strong preliminary results strengthen the company's negotiating position and may support a higher valuation in final deal terms. For practice owners, the revenue beat reflects continued demand for Morpheus8 RF microneedling, fractional CO2 (ResurFX), and diode platforms, suggesting the installed base remains active and consumables-driven.
InMode projects Q2 revenue of $95.2M–$95.4M, tracking above consensus while takeover bids remain unresolved.
The guidance also signals that operational momentum has not been disrupted by the takeover process. Full results on August 5 will clarify mix (consumables vs. capital equipment), geographic performance, and any color on distributor inventory or rebate program changes.
Source: original report ↗
Free alerts Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.
